OPC 41061 IN PTS WITH HYPONATREMIA SECONDARY TO LIVER DISEASE

OPC 41061 在继发于肝病的低钠血症患者中的应用

• 批准号: 6275428
• 负责人: BAHRI M BILIR
• 金额: $ 3.14万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6275428
• 关键词: clinical research; dosage; electrolyte balance; hormone inhibitor; hormone receptor; human subject; human therapy evaluation; hyponatremia; liver disorder; liver disorder chemotherapy; vasopressins

The goal of this study is to find a dose titration curve for the effectiveness of a new vasopressin ii receptor antagonists in patients with hyponatremia secondary to liver disease. In this multicenter study it is expected that 30 to 60 mg dose of this new medication (based on the phase i study) will be effective in initiating adqueresis. This is a placebo controlled, double blinded, multicenter study with several phases where dose of the medication is increased after a careful evaluation of the previous dose by a conference call among the participating investigators.

本研究的目的是找到一个剂量滴定曲线， 一种新的血管加压素Ⅱ受体拮抗剂在病人中的疗效 继发于肝病的低钠血症 在这项多中心研究中， 预计30至60 mg剂量的这种新药（基于 第一阶段研究）将有效启动提取。 这是一 安慰剂对照、双盲、多中心研究，包括几个阶段 在仔细评估后增加药物剂量， 通过参与者之间的电话会议 investigators.